Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Drugs2,045100%2,418100% +18.23%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
United States1,02650.1%1,30654% +27.35%
Europe633.2031%620.3225.7% -2.03%
Japan190.069.3%258.2610.7% +35.88%
Other167.868.2%201.648.3% +20.12%
Switzerland28.391.4%31.691.3% +11.64%
Managers
NameAgeSinceTitle
Jean-Paul Clozel621997Chief Executive Officer & Executive Director
Jean-Pierre Garnier692011Chairman
Otto Schwarz622008Chief Operating Officer & Executive Vice President
André C. Muller, MBA542013Chief Financial Officer & Executive Vice President
Martine Clozel, MD621997Chief Scientific Officer & Senior Vice President
Michael Jacobi, PhD642009Independent Non-Executive Director
Jean Pierre Malo CFA, MBA632004Independent Non-Executive Director
Juhani Anttila63-Independent Non-Executive Director
Robert J. Bertolini, CPA54-Independent Non-Executive Director
Peter Gruss, PhD682012Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 107,761,427 93,832,489 87.1% 4,654,225 4.3% 87.1%
Shareholders
NameEquities%
Rudolf Maag, MBA 5,467,305 5.07%
Jean-Paul Clozel 5,418,507 5.03%
Norges Bank Investment Management 3,333,050 3.09%
Actelion Ltd. 3,257,940 3.02%
The Vanguard Group, Inc. 2,033,898 1.89%
UBS AG (Investment Management) 1,788,834 1.66%
Bellevue Asset Management AG 1,719,871 1.60%
Credit Suisse AG 1,379,788 1.28%
BlackRock Investment Management (UK) Ltd. 1,030,674 0.96%
BlackRock Fund Advisors 958,634 0.89%
Holdings
NameEquities%Valuation
Actelion Ltd (ATLN) 3,257,9403.02%879,346,089 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ACTELION LTD24.72%29 697
AMGEN, INC.13.56%122 281
CELGENE CORPORATION6.45%95 861
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
VERTEX PHARMACEUTICALS..20.88%22 123
GENMAB A/S18.93%12 257
TESARO INC14.23%8 238
EXELIXIS, INC.36.22%5 908
HUALAN BIOLOGICAL ENGI..--.--%4 996
TONGHUA DONGBAO PHARMA..-2.46%4 411
KITE PHARMA INC66.15%4 085
NEUROCRINE BIOSCIENCES..7.24%3 615
BLUEBIRD BIO INC40.92%3 551
BIOCON LTD19.89%3 449
CLOVIS ONCOLOGY INC54.28%3 058
ULTRAGENYX PHARMACEUTI..2.39%3 004
INTERCEPT PHARMACEUTIC..6.58%2 875
PEPTIDREAM INC-12.99%2 722
CHINA BIOLOGIC PRODUCT..-7.48%2 704
BEIJING SL PHARMACEUTI..--.--%2 671
Sector Bio Therapeutic Drugs
Actelion Ltd : Connections
Alzheon, Inc.
Actelion Pharmaceuticals Italia SRL
Actelion Pharmaceuticals Hellas SA
Avalon Advisors LLC
Actelion Pharmaceuticals Japan Ltd.
Actelion Pharmaceuticals Korea Ltd.
Deutsche Akademie der Technikwissenschaften eV
Actelion Pharmaceuticals Sverige AB
Society of Financial Analysts of Houston
ArgYou AG
ValCrea AG
Max Planck Institute For Biophysical Chemistry
Newman's Own Foundation
Anttila & Co. Advisors
Hilti Martin Family Trust
The Francis Crick Institute Ltd.
Hilti AG
Actelion Pharmaceuticals UK Ltd.
Deutsche Forschungsgemeinschaft
CFA Institute
Deutsche Akademie der Naturforscher Leopoldina eV
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  
- Reuters Code :  ATLN.S
- Datastream Code :  S:ATLN
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem